Safety and efficacy of Methotrexate Monotherapy Vs Methotrexate plus Leflunomide Combination Therapy in Early Active Rheumatoid Arthritis Patients
MTX has long been considered as the anchor drug in RA treatment, however given, its high failure rate and the multifactorial nature of the disease, there has been a great interest in developing more powerful and tolerable MTX combination therapies. Leflunomide has long been appreciated to be a suitable alternative therapy used on its own or with MTX due to its equivalent efficacy and structural similarity. The aim of the study was to compare the efficacy and safety of a combination therapy of MTX plus LEF to MTX alone when used with early active rheumatoid arthritis patients. Fifty female patients with early active RA were randomly allotted in two groups each of 25. Patients were randomized to receive MTX or MTX+LEF. Analysis of DAS28 score, complete blood picture, and liver enzymes at the start and post 24 weeks of treatment with study regimens was performed, compared and evaluated. MTX+LEF combination therapy was more significantly beneficial in decreasing DAS28 score compared to MTX alone. The combination therapy showed less effect on blood components, but was more hepatotoxic compared to MTX monotherapy. The combination therapy is a more attractive option to consider especially in early active RA patients than MTX monotherapy. It is more clinically beneficial in improving disease outcomes, well tolerated, with less hematological toxicity and only showed mild hepatotoxicity. Taken into consideration proper monitoring of liver toxicity, this combination is safe and more effectively intervene early in the disease process thus preventing future possible complications and aiming better remission
___
1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.2. Ding CZ, Yao Y, Feng XB, Fang Y, Zhao C, Wang Y. Clinical analysis of chinese patients with rheumatoid arthritis treated with leflunomide and methotrexate combined with different dosages of glucocorticoid. Curr Ther Res Clin Exp. 2012;73(4-5):123-33.
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, RubbertRoth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
4. Van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-41.
5. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82.
6. Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007;3(8):450-8; quiz, following 478.
7. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis.Clin Ther. 2004;26(4):447-59.
8. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol. 2011;23(3):288-92.
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
10. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
11. Caporali R, Conti F, Alivernini S, Atzeni F, Seriolo B, Cutolo M, Valesini G,Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M; Italian Society for Rheumatology. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29(3 Suppl 66):S7-14.
12. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev. 2014;13(11):1102-8.
13. Londono J, Santos AM, Santos PI, Cubidez MF, Guzman C, Valle-Oñate R. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Rev Bras Reumatol. 2012;52(6):837-45. 14. Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum. 2011;40(5):371-88.
15. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9):726- 33.
16. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis (Review). Cochrane Database Syst Rev. 2010;(4):CD008495.
17. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004;31(8):1521-31.
18. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(1):CD002047.
19. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 1995;38(11):1595-603.
20. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I,Oed C, Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353(9149):259-66.
21. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159(21):2542-50.
22. Martin K, Bentaberry F, Dumoulin C, Dehais J, Haramburu F, Bégaud B, Schaeverbeke T. Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials. Clin Exp Rheumatol. 2005;23(1):80-4.
23. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, Salisbury D, Singh JA, Stern R, Zarabadi SA. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum. 2003;49(6):745-51.
24. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69(1):43-7.
25. Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, Park YB. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther. 2012;14(5):R232.
26. Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol. 2013;40(3):228-35.
27. Gupta R, Gupta SK. Severe Hepatotoxicity in a Rheumatoid Arthritis Patient Switched From Leflunomide to Methotrexate. MedGenMed. 2005;7(3):9.
28. The European Agency for the Evaluation of Medicinal Products. EMEA issues public statement on leflunomide. Reactions Weekly. 2001;844:2. Updated 2014.
29. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43(3):267-71.
30. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989;32(12):1592-6.
31. öttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum.0 2002;46(4):894-8.
32. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis: technology appraisal guidance, no 36. London: National Institute for Clinical Excellence. 2002. http://www.spitjudms.ro/_files/protocoale_terapeutice/reumatologie/ghid%20de%20tratament%20in%20par.pdf access date 03.07.2015
- ISSN: 2147-0634
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 2012
- Yayıncı: Effect Publishing Agency ( EPA )
Sayıdaki Diğer Makaleler
Heba Farouk SALEM, Mohamed Nabil Abd El HAMİD, Amira Shaban AHMED, Rania M. SARHANL
Atrial Fibrillation at a Very Young Age
Afşin EMRE KAYIPMAZ, Abuzer COŞKUN, Sedat ÖZBAY, Osman Mahir OKUR, Ilham OZKAN, Hakkı KAYA, ŞEVKİ HAKAN EREN, Cemil KAVALCI, Mehmet Ali KARACA
Hypothermia Frequency of Patients in the Postoperative Period
Münire BABAYİĞİT, Zehra BAYKAL TUTAL, Handan GÜLEÇ, Necla DERELİ, Seda İLHAN, Mustafa Alparslan BABAYİĞİT, Eyüp HORASANLI
Hassna OSAMA, Hoda Abd Elbadie HUSSEİN, Mohamed E. ABDELRAHİM, Heba F SALEM
An Atypical Complex Regional Pain Syndrome Type 1 Following Diphtheria-Tetanus Vaccination
Ergenekon KARAGÖZ, Emre ATA, Murat KOSEM, Emre ERSOZ, Selim AKARSU, Vedat TURHAN
Akut Koroner Sendromlu Hastalarda Kardiyak Rehabilitasyon
Risk Factors for Gestatıonal Diabetes in Women with Polycystic Ovarian Syndrome
Senem Arda DUZ, Ilgın TÜRKÇÜOĞLU
Alpaslan TANOĞLU, Ergenekon KARAGÖZ, Asım ÜLÇAY, Vedat TURHAN, Muammer KARA, YUSUF YAZGAN
High Dose Sugammadex Administiration in a Case of Huntington Chorea
Mehmet SARGIN, MEHMET SELÇUK ULUER, Sadık ÖZMEN
The Value of Tc-99m Mibi for Differential Diagnosis of Biliary Atresia and Hepatitis in Rats
Ismail KOKSAL, Ersoy KEKİLLİ, Reyhan KÖROĞLU, Fatih BATİ, Abdurrahman KARAMAN, Alaattin POLAT